Unknown

Dataset Information

0

Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study.


ABSTRACT: Background Clinical observations and results from recent studies support the use of non-invasive vagus nerve stimulation (nVNS) for treating cluster headache (CH) attacks. This study compared nVNS with a sham device for acute treatment in patients with episodic or chronic CH (eCH, cCH). Methods After completing a 1-week run-in period, subjects were randomly assigned (1:1) to receive nVNS or sham therapy during a 2-week double-blind period. The primary efficacy endpoint was the proportion of all treated attacks that achieved pain-free status within 15 minutes after treatment initiation, without rescue treatment. Results The Full Analysis Set comprised 48 nVNS-treated (14 eCH, 34 cCH) and 44 sham-treated (13 eCH, 31 cCH) subjects. For the primary endpoint, nVNS (14%) and sham (12%) treatments were not significantly different for the total cohort. In the eCH subgroup, nVNS (48%) was superior to sham (6%; p?

SUBMITTER: Goadsby PJ 

PROVIDER: S-EPMC5896689 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study.

Goadsby Peter J PJ   de Coo Ilse F IF   Silver Nicholas N   Tyagi Alok A   Ahmed Fayyaz F   Gaul Charly C   Jensen Rigmor H RH   Diener Hans-Christoph HC   Solbach Kasia K   Straube Andreas A   Liebler Eric E   Marin Juana Ca JC   Ferrari Michel D MD  

Cephalalgia : an international journal of headache 20171212 5


Background Clinical observations and results from recent studies support the use of non-invasive vagus nerve stimulation (nVNS) for treating cluster headache (CH) attacks. This study compared nVNS with a sham device for acute treatment in patients with episodic or chronic CH (eCH, cCH). Methods After completing a 1-week run-in period, subjects were randomly assigned (1:1) to receive nVNS or sham therapy during a 2-week double-blind period. The primary efficacy endpoint was the proportion of all  ...[more]

Similar Datasets

| S-EPMC5113831 | biostudies-literature
| S-EPMC6791025 | biostudies-literature
| S-EPMC6637721 | biostudies-literature
| S-EPMC6755582 | biostudies-other
| S-EPMC6755599 | biostudies-literature
| S-EPMC4840129 | biostudies-literature
| S-EPMC6742918 | biostudies-literature
| S-EPMC4853813 | biostudies-literature
| S-EPMC9216713 | biostudies-literature
| S-EPMC9588751 | biostudies-literature